Table of Contents Table of Contents
Previous Page  684 / 812 Next Page
Information
Show Menu
Previous Page 684 / 812 Next Page
Page Background

S680

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

50–150mg daily. After confirming parkinsonism signs, psychia-

try proceeds to changing pharmacology, with slow decline until

suspension of antipsychotics, paroxetine by venlafexina change,

and also change of antihypertensive (captopril). After review at 2

months it is seen signs of improvement parkinsonism, appreciating

the mental patient improvement with decreased physical discom-

fort and keeping the improvement in the last review (4 month)

with venlafaxine 150mg/day, Lorazepam 1mg casual. The preva-

lence of drug-induced Parkinson’s can go from 15 to 32% of the

population. Risk factors identified are: advanced age, family pre-

disposition, doses and drug power inductor, female gender and the

presence of brain atrophy. The main objective should be to prevent

the onset of Parkinson drug, to monitor patients that may be at

higher risk of developing it.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2019

EV1035

Doctor I have painful erections

F. Medini

, L. Menif , G. Jmii , F. Ghali , M. Zeghal ,

L. Robbana , S. Derouiche , W. Melki

Hospital razi, psychiatry D, Jardin D El Menzah, Tunisia

Corresponding author.

Introduction

Ischemic (veno-occlusive, low flow) priapism is a

painful and persistent penile erection unrelated to sexual desire or

stimulation. In some cases, it is an adverse event of antipsychotic

medications.

Materials and methods

An Internet search was initiated using

the search engines: Direct Sciences; Medline and keywords “Penile

erection; priapism; Antipsychotic agents; Side effects” andwe illus-

trated our literature review by a clinical vignette of a man aged

38 years followed for schizophrenia placed under Fluphenazine

125mg/month from5 years who consulted us inmay 2015 because

of priapism and he described painful and prolonged erection

episodes evolving for approximately 5 days.

Discussion

Medical literaturementionsmany cases of venous pri-

apism in patients treated by conventional or atypical neuroleptics.

About 30% of venous priapisms could be related to drugs of which

approximately 50% to neuroleptics. This side effect is related to

alpha1-adrenergic blocking properties of these treatments, more

or less important depending on the drugs in this class. After emer-

gency treatment, the priapism is the problem of the continued

neuroleptic treatment. The substitution of onemolecule by another

alpha-1 blocking properties to the less marked is recommended.

Conclusion

The venous priapism is a uro-andrological emergency

requiring prompt treatment to prevent erectile sequelae.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2020

EV1036

Modulation of corticospinal

excitability by valerian officinalis root

extract: A neuropharmacological

Transcranial Magnetic Stimulation

(TMS) study

L. Mineo

1 ,

, C . C

oncerto

1 , Y. S

arraf

2 , E. G

iokas

2 , M.

Paula

2 ,

D. Coira

3

, C. Ellen

2

, E. Aguglia

1

, F. Battaglia

4

1

Unit of Psychiatry, Department of clinical and experimental

medicine, Catania, Italy

2

New York College of Podiatric Medicine, Department of Preclinical

Sciences, New York, USA

3

Hackensack University Medical Center, Psychiatry and Behavioral

Medicine, Hackensack, NJ, USA

4

Seton Hall University, Health and medical sciences, South Orange,

USA

Corresponding author.

Introduction

Valerian officinalis roots extract is a popular med-

ication for insomnia and anxiety treatment. Sedative effect of

Valerian is mainly attributed to the modulation of gabaergic trans-

mission, but its pharmacodynamics has not been fully elucidated.

Objects

To investigate the acute effects of Valerian Officinalis

extracts intake on corticoexcitability as measured by TMS.

Aims

To obtain further data on Valerian pharmacodynamics.

Methods

Twelve healthy volunteers participated in a double-

blind randomized crossover placebo-controlled study. They were

required to take either 900mg of Valerian officinalis extract

(valerenic acid 0.8%) or placebo. Focal TMS of the hand area of

left motor cortex was used to test Resting motor threshold (RMT),

Motor evoked potentials (MEPs) amplitude and silent period dura-

tion (SP). We also tested Short-interval Intracortical Inhibition

(SICI), Intracortical facilitation (ICF), Short and Long afferent Inhi-

bition (SAI and LAI). All parameters were investigated at baseline,

1 hour and 6 hours after drug intake. After a 3-weekwashout period

the subjects switched to the alternate arm of the study.

Results

A mixed RMANOVA revealed a significant main effect of

“time” [F

(1,22)

= 4.03,

P

= 0.02] and a significant “treatment

×

time”

interaction [F

(1,22)

= 6.3,

P

= 0.003]. Post-hoc analysis indicated that

the amount of ICF was significantly reduced 1 hour after Valerian

intake (

P

= 0.01) returning to baseline values after 6 hours. No sig-

nificant changes between the Valerian and placebo groups were

observed for the other parameters investigated.

Conclusions

Themodulation of ICF induced by Valerian officinalis

is likely due to glutamatergic antagonism and might underlie the

anti-anxiety therapeutic effects.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2021

EV1037

Tolerability of desvenlafaxine in

clinical practice: An observational

phase-IV study

B. Navarro

1 ,

, I. Perez

2

, L. Perez

1

, L. Erkoreka

1

, A. Arroita

1

1

Red de Salud Mental de Bizkaia, CSM Barakaldo, Bilbao, Spain

2

Hospital Universitario Cruces, psiquiatría, Barakaldo, Spain

Corresponding author.

Introduction

Desvenlafaxine is a SNRI which presents lowaffinity

for muscarinic, H1 and 1 in vitro receptors and a marginal hep-

atic metabolism. Different studies have shown effectiveness and

a favorable tolerability profile, but only a few of them have been

realized independently.

Objectives and aims

To study the incidence and characteristics of

short-termdesvenlafaxine side effects (SE) in daily clinical practice.

Methods

A total of 123 patients with recently introduced desven-

lafaxine treatment are recruited from Barakaldo and Uribe-Kosta

Mental Health Centers, and UKU scale is administered to measure

SE. Descriptive data are calculated using SPSS v.22.

Results

SE are observed in 30.09%. Among these, 5.69% experi-

mented improvement or disappearance of SE with dose reduction,

whereas 16.26% had to stop DVF treatment. The most frequent SE

was nausea/vomiting (7.3%), followed by dry mouth (4.9%), blurred

vision (4.9%), tachycardia (4.1%), sexual SE (4.1%) and tension/inner

unrest (4.1%). Among the patients with anxiety disorders, 27.78%

present SE versus 30.47% of patients with other diagnoses.

Conclusions

The characteristics of SE with DVF in daily clinical

practice are comparable to those found in previous studies, and

the overall profile is more benign than other AD. Aspects such

as gender and sexual function must be considered. In patients

with anxious symptoms DVF is also effective and ES are presented